

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**INNOCARE**

诺 诚 健 华

**InnoCare Pharma Limited**

**諾誠健華醫藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 9969)**

## **DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of InnoCare Pharma Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on Thursday, 13 November 2025 for the purpose of, among other matters, considering and approving the unaudited third quarterly results of the Company and its subsidiaries for the nine months ended 30 September 2025 and its publication.

By order of the Board of  
**InnoCare Pharma Limited**  
**Dr. Jisong Cui**

*Chairperson and Executive Director*

Hong Kong, 31 October 2025

*As at the date of this announcement, the Board comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi and Mr. Ronggang Xie as non-executive Directors, and Ms. Lan Hu, Dr. Dandan Dong and Prof. Kunliang Guan as independent non-executive Directors.*